Molecular Biomarkers of Cancer Stem/Progenitor Cells Associated with Progression, Metastases, and Treatment Resistance of Aggressive Cancers

Murielle Mimeault and Surinder K. Batra

Abstract

The validation of novel diagnostic, prognostic, and predictive biomarkers and therapeutic targets in tumor cells is of critical importance for optimizing the choice and efficacy of personalized therapies. Importantly, recent advances have led to the identification of gene-expression signatures in cancer cells, including cancer stem/progenitor cells, in the primary tumors, exosomes, circulating tumor cells (CTC), and disseminated cancer cells at distant metastatic sites. The gene-expression signatures may help to improve the accuracy of diagnosis and predict the therapeutic responses and overall survival of patients with cancer. Potential biomarkers in cancer cells include stem cell–like markers [CD133, aldehyde dehydrogenase (ALDH), CD44, and CD24], growth factors, and their cognate receptors [epidermal growth factor receptor (EGFR), EGFRvIII, and HER2], molecules associated with epithelial–mesenchymal transition (EMT; vimentin, N-cadherin, snail, twist, and Zeb1), regulators of altered metabolism (phosphatidylinositol-3 kinase/Akt/mTOR), and drug resistance (multidrug transporters and macrophage inhibitory cytokine-1). Moreover, different pluripotency-associated transcription factors (Oct3/4, Nanog, Sox2, and Myc) and microRNAs that are involved in the epigenetic reprogramming and acquisition of stem cell–like properties by cancer cells during cancer progression may also be exploited as molecular biomarkers to predict the risk of metastases, systemic treatment resistance, and disease relapse of patients with cancer.

Cancer Epidemiol Biomarkers Prev; 23(2); 234–54. ©2013 AACR.

Introduction

Significant advancement in basic and clinical oncology during the last few years has led to earlier diagnosis and more effective therapeutic management of patients with leukemias and organ-confined tumors in the clinics (1–3). Although the surgical tumor resection may result in some cases to a complete remission, the rapid cancer progression of aggressive cancers to locally invasive and metastatic stages is generally associated with the development of resistance mechanisms by cancer cells to current anti-hormonal, radiation, and/or chemotherapeutic treatments and disease relapse (1–3). At the present time, the metastatic cancers remain the leading cause of the death of patients with cancer. Therefore, many research efforts have been made to identify and validate novel molecular biomarkers and therapeutic targets in cancer cells at primary and secondary tumors to prevent cancer progression and metastases and optimize the genetic- and proteomic-based individualized treatments of patients with cancer (Fig. 1; refs. 4–28).

Importantly, accumulating lines of evidence have revealed that the shedding of cancer cells from the primary tumors into the lymphatic vessels and peripheral circulation can occur very early during the cancer development and be dependent of cellular origin, genetic alterations, and aggressiveness of cancer subtypes (16, 29–41). Hence, some patients who undergo a complete surgical tumor resection with negative margins may show the presence of circulating tumor cells (CTC) in the peripheral blood and disseminated tumor cells at the regional lymph nodes and distant tissues and organs (Fig. 1; refs. 16, 29–41). Consequently, CTCs that are able to survive in the bloodstream and spread at distant sites can persist and contribute to metastases and disease relapse even after an effective and apparently curative surgical resection of the primary tumor. In this regard, a growing body of experimental evidence has also revealed that cancer stem/progenitor cells endowed with stem cell–like properties, also designated as cancer-, tumor-, and metastasis-initiating cells, can provide critical functions for tumor growth, metastases at near and distant tissues and organs, treatment
resistance, and disease relapse. In fact, it has been shown that the most cancers may originate from the malignant transformation of immature tissue-resident stem/progenitor cells or their early differentiated progenies endowed with a high self-renewal ability and aberrant differentiation potential (2, 42–44). The cancer stem/progenitor cells expressing specific stem cell–like markers such as CD133, CD44high, nestin, aldehyde dehydrogenase (ALDHhigh), and high levels of ATP-binding cassette (ABC) multidrug transporters have also been identified and isolated from primary and secondary neoplasms, including leukemias, melanomas, brain tumors, and the most epithelial cancers and cancer cell lines (9,17, 24, 44–76). It has been shown that cancer stem/progenitor cells were able to give rise to the total tumor cell mass, including differentiated cancer cells that reconstituted the histological architecture and molecular characteristics of primary and secondary tumors closely resembling to original patient’s tumors in vivo (9, 17, 45–57, 59–66, 68, 69, 71, 77). Moreover, the data from recent studies have indicated that cancer stem/progenitor cells may be more resistant than their differentiated progenies to current antihormonal, radiation and chemotherapeutic treatments, and targeted therapies (17, 22–25, 44, 52, 53, 56–64, 68, 70, 72, 77–94).

We review here recent advances on the characterization of gene products often altered in cancer stem/progenitor cells and their differentiated progenies during primary cancer progression and dissemination through the peripheral circulation and metastases. The emphasis is on molecular gene signatures, epithelial–mesenchymal transition (EMT)-like and stem cell–like biomarkers detected in cancer cells and exosomes associated with cancer progression, treatment resistance, disease relapse, and poor outcome of patients with cancer.

Heterogeneity of Cancers

The most cancers are heterogeneous diseases and include some biological subtypes characterized by specific genetic and/or epigenetic alterations occurring in cancer stem/progenitor cells and their differentiated progenies during primary cancer initiation and progression to locally invasive and metastatic stages (4, 6, 7, 44, 60, 78, 80, 95–109). Although the molecular events that govern the spread of cancer stem/progenitor cells and their differentiated progenies at preferential metastatic sites remain not precisely defined, some lines of evidence suggest that particular gene signatures of cancer cells at primary cancers may be
associated with their propensity at metastasizing at specific tissues and organs (4, 6, 7, 95–102). More particularly, the alterations in the gene products involved in the acquisition of aggressive and migratory properties by highly tumorigenic cancer stem/progenitor cells during the EMT program at the primary tumor may result in their invasion to near lymph nodes and tissues, dissemination through the peripheral circulation, and metastases at distant sites (Fig. 1; refs. 30, 42, 90, 91, 96, 97, 110–126). Moreover, different gene products have also been identified in exosomes released by tumor cells and CTCs with stem-cell-like features that may be used as diagnostic, prognostic, and/or predictive biomarkers. In this regard, we review the gene products frequently altered in cancer cells, during cancer progression to locally advanced and metastatic states, exosomes and CTCs that have been associated with treatment resistance, disease relapse, and poor overall survival of patients with cancer.

Molecular gene signatures and stem cell-like biomarkers associated with aggressive and metastatic cancers

Some tissue-specific and whole genome approaches for molecular profiling of complex gene signatures of tumors and cancer cell lines have been developed in the last few years and led to the discovery of specific gene sets related to particular cancer types and which may predict the risk of metastatic dissemination at specific tissues and organs and overall outcome of patients with cancer (Fig. 1; refs. 4–15). Moreover, the in vitro and in vivo characterization of stem cell–like markers and functional features of cancer stem/progenitor cells in tumor tissue specimens from patients with cancer and cancer cell lines has also revealed their major implications in tumor growth, metastases, treatment resistance, and disease relapse (Fig. 1; refs. 15–27). We are reporting here the gene signatures and stem cell–like biomarkers of cancer cells associated with particular subtypes of aggressive cancers, including hormone-independent prostate and breast cancers.

Prostate cancer

Prostate cancer is among the most commonly diagnosed malignancies affecting men (127–129). Although an earlier diagnosis of patients with prostate cancer has led to an improvement of their effective treatment by tumor resection surgery and/or radiation therapy, the locally advanced and metastatic castration-resistant prostate cancers (CRPC) still represent the second leading cause of cancer-related death (127–129). In fact, antihormonal treatments and first-line docetaxel-based chemotherapies of metastatic CRPCs are only palliative and result in the death of most patients after about 12 to 19 months (127–129). Therefore, this inefficacy of current treatments against CRPCs underlines the importance to identify novel biomarkers to predict the risk of propagation to CRPCs. Of clinical relevance, a 11-gene signature related to the activation of polycomb-group protein BMI-1 pathway, which provides critical functions for the self-renewal of diverse normal and cancer stem cells, has notably been identified through a comparative genomic approach using primary and metastatic tumor specimens from transgenic adenocarcinoma of the mouse prostate model and patients with prostate cancer (4). The 11-gene signature includes 8 upregulated genes (Ki67, cyclin B1, gastrulation brain homeobox 2, budding uninhibited by benzimidazoles 1 "BUB1" that acting as serine/threonine-protein kinase, kinetochore associated 2, ubiquitin-specific protease 22, host cell factor 1, and ring finger protein 2) and 3 downregulated genes (ankyrin 3, fibroblast growth factor receptor 2, and carboxylesterase 1; ref. 4). This 11-gene signature, which is associated with an upregulation of stem cell–ressembling expression profile of the BMI-1–regulated pathway, has been shown to be a powerful predictor of patients with prostate cancer progression to locally invasive and metastatic stages (4). The analyses of this 11-gene signature of BMI-1–driven pathway in 1,153 clinical tumor specimens from patients with cancer diagnosed with 11 different types of cancer have also indicated that the expression of these gene products was associated with a short interval to disease recurrence, distant metastases, and death after therapy of patients with cancer (4). These cancer types comprise acute myeloid leukemia, lymphoma, mesothelioma, medulloblastoma, glioma, and prostate, breast, lung, ovarian, and bladder epithelial cancers (4). Importantly, high expression levels and/or activities of stem cell–like markers such as CD133, CD44, integrin-α2/CD44, nestin, ALDH1, and CD49f in primary prostatic adenocarcinomas and bone metastases from patients and prostate cancer cell lines have also been associated with their aggressive and invasive phenotypes and treatment resistance (17–26, 28). Particularly, the data from immunohistochemical analyses of integrin-α2, integrin-α6, and hepatocyte growth factor receptor (MET) in prostate cancer cells have revealed that an increase of expression levels of these markers in prostatic adenocarcinoma specimens from patients with prostate cancer was associated with an enhanced risk of local invasion and bone metastasis (130). It has also been reported that several ALDH isoforms were expressed in specimens of primary prostate tumors with matched bone metastases and prostate cancer cell lines, and ALDH1high PC3M-Pro4 cells rapidly formed primary prostatic tumor and metastasized at distant sites in vitro as compared with ALDH1low PC3M-Pro4 cells (18, 19). Of therapeutic interest, the knockdown of ALDH7A1 expression in PC3M-Pro4 cells has also been observed to result in a decrease of the integrin-α2high/integrin-α6high/CD44+ PC3M-Pro4 stem/progenitor cell subpopulation and gene products involved in the EMT process and invasion, including snail, snail2, twist, and extracellular molecule, osteopontin (19). Moreover, the ALDH7A1 silencing in PC3M-Pro4 cells significantly inhibited their clonogenic and migratory abilities in vitro as well as their capacity to form bone metastases in vivo (19). In the same way, it has also been observed that prostate-specific antigen (PSA−F) prostate cancer cells from LNCaP, LAPC4, or LAPC9 cell lines or tumor
specimens from patients with prostate cancer expressing stem cell–like markers such as ALDH1, CD44, integrin-α3β1, and with a long-term tumor-propagating ability were able to give rise to the total mass of PSA+/lo prostate cancer cells in vitro (17). It has also been noted that PSA−/lo LAPC9 cells were resistant to androgen deprivation in castrated hosts, and high grade and recurrent prostatic adenocarcinoma specimens of patients were enriched in PSA−/lo prostate cancer cells (17). These observations suggest that PSA−/lo prostate cancer cells may play critical functions for the tumor regrowth after antihormonal treatment initiation.

In addition, we have observed that sonic hedgehog (SHH/GLI-1), epidermal growth factor receptor (EGFR), pAkt, nuclear factor-xB (NF-xB), and macrophage inhibitory cytokine-1 (MIC-1) are frequently overexpressed in prostate cancer cells, including CD133+ prostate cancer stem/progenitor cells, detected in prostate adenocarcinoma and bone metastasis specimens from patients with prostate cancer (23, 24). The high expression levels and/or activities of these oncogenic products were also detected in the side population from tumorigenic and invasive WPE1-NB26 cells and metastatic PC3M-LN4 endowed with a high prostasphere-forming ability (23–25). Moreover, the targeting of hedgehog, EGFR, pAkt, NF-xB, or MIC-1 by using cyclopamine, gefitinib, Akt inhibitor III, partenolide, or anti-MIC-1 antibody was effective at inducing the apoptotic effects on side population and non-side population cells from WPE1-NB26 and PC3M-LN4 cell lines and improving cytotoxic effects induced by docetaxel on these side population and non-side population cells (23, 24). Recent studies have also revealed that the changes in the expression levels and activities of hypoxia-inducible factors (HIF) and microRNAs (miRNA), which are short noncoding RNA molecules of about 22 nucleotides that are involved in the stringent control of normal stem cell behavior often occur in cancer cells including prostate cancer cells (27, 28, 131, 132). HIFs and miRNAs may be involved in the epigenetic reprogramming and acquisition of stem cell–like features by cancer cells (27, 28, 131, 132). More specifically, the upregulation of HIF-1α and HIF-2α has been associated with the increased expression of pluripotency-associated transcription factors (Nanog, Oct4, and Sox2) and EMT program-associated molecules in prostate cancer cells under normoxic and hypoxic conditions during prostate cancer progression to locally invasive and metastatic stages (27, 28). The downregulation of some tumor-suppressor miRNAs such as mi-R34a, let-7b, miR-106a, and miR-141 combined with an upregulation of miR-301 and miR-452 has also been observed to regulate the proliferation and tumorigenicity of CD133+/CD44+integrin-α3β1 prostate cancer stem/progenitor cell population and side population cells in vitro and in vivo (131, 132).

Breast cancer

Breast cancer is among the most common cancers in women (127, 133, 134). Although a high survival rate is observed for early-stage patients with breast cancer treated by tumor resection surgery and adjuvant treatments, the propagation to locally invasive and metastatic disease state is generally associated with the development of resistance mechanisms by cancer cells to current antihormonal treatments, targeted therapies, radiation, and chemotherapy (127, 133, 134). Typically, breast cancer is a complex and highly heterogeneous disease that encompasses distinct cancer subtypes characterized by the malignant transformation of the basal and/or luminal breast epithelial cells in the mammary gland (135, 136). In this regard, the data from analyses of the expression levels of gene products in breast cancer cells, including breast cancer stem cells (BCSCs) with stem cell–like features, have indicated that breast cancer subtypes may exhibit cellular and functional heterogeneities (5–14, 137, 138). It has been observed that CD44high+/CD24low BCS are frequently detected in basal-like subtypes of breast cancer whereas these immature cancer cells are very low in erbB2/HER2 breast tumors (8). Moreover, a transcriptional analysis of basal-like breast cancer cell lines has led to the identification of 2 major cancer subclasses in which basal B seemed mesenchymal-like, whereas basal A may have either a luminal-like or basal-like morphology. It has been observed that a CD44high+/CD24low epithelial basal A cell subpopulation isolated from triple-negative HMT3909S13 breast cancer cell line exhibited cancer stem cell features such as mammosphere formation and resistance to the standard chemotherapy as well as tumor-initiating capacity in vivo (6). In contrast, CD44high+/CD24low mesenchymal-like basal B cell fraction does not exhibit these functional features (6). The data from comparative quantitative proteomic and gene array analyses of CD44high+/CD24low BCSCs with an epithelial-like morphology have also indicated that these immature cancer cells expressed lipolysis-stimulated lipoprotein receptor, RAB25, S100A14, and mucin 1 (MUC1; ref. 6). These CD44high+/CD24low BCSCs also expressed a novel 31-gene signature that was related at the presence of distant metastases in estrogen receptor negative (ER−)-human breast cancer specimens (6). Conversely, the results from another investigation have revealed that CD44high+/CD24low BCSCs that were detected in patient’s primary tumors exhibited a gene signature as the claudin-low molecular subtype, which is characterized by the expression of several EMT program-associated molecules (10). It has been noted that the CD44high+/CD24low BCSCs expressing mesenchymal markers were enriched in patient’s primary tumors after either endocrine letrozole-based therapy or docetaxel-based chemotherapy (10). These findings suggest that breast cancer cells endowed with an epithelial or mesenchymal phenotype can exhibit cancer stem cell properties dependent on breast cancer subtypes and be involved in the metastasis formation and treatment resistance.

On the other hand, the data from analyses of global gene expression profiles have also indicated that a common subset of 81 genes was differentially expressed between
ER− and ER+ breast tumor specimens and breast cancer cell lines as well as in androgen-independent versus androgen-sensitive prostate cancer cell lines (11). It has been noted that some signaling elements of EGFR pathway were enriched in ER− breast and androgen-independent prostate cancer cell lines, suggesting that the sustained activation of this tumorigenic cascade may contribute to the growth and survival of these hormone-independent cancer cells (11). Interestingly, it has been reported that an 8-gene signature (EGFR, integrin-α3, myosin light chain kinase, retinoic acid–induced protein 14, AHNAK nucleoprotein, glutaminase, interleukin-32, and nicotinamide N-methyltransferase) was associated with the invasion and sensitivity of a panel of 78 tumor cell lines to chemotherapeutic drugs, including paclitaxel, docetaxel, erlotinib, everolimus, and dasatinib (14). This set of 8 genes also predicted the relapse-free survival for patients with breast cancer (14).

**Other cancer types**

Recent investigations have also led to the discovery of specific gene signatures and potential biomarkers in cancer tissue specimens for improving the personnel management of patients with other aggressive cancers such as brain, melanoma, esophageal squamous cell carcinoma (ESCC) and lung, pancreatic, colorectal, esophageal, and ovarian cancers (Table 1; refs. 3, 14, 70, 139–149). For instance, the real-time PCR data from gene expression profiles of brain tumor stem-like cells (BTSCs) from 5 human glioblastoma multiforme (GBM) and matched GBM tissue specimens have indicated that SHH and GLI1 hedgehog signaling elements were coexpressed only at GBM tissue specimens have indicated that SHH and GLI1 hedgehog signaling elements were coexpressed only at high levels in BTSCs 1 to 3 and not in BTSCs 4 and 5 (141). It has also been noted that the SHH/GLI1 hedgehog signaling elements were coexpressed only at high levels in BTSCs 1 to 3 and not in BTSCs 4 and 5 (141). Of clinical interest, higher expression levels of SHH, patched receptor 1 (PTCH1), and GLI1 have also been detected in phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-expressing brain tumors than in PTEN-deficient brain tumors and associated with a poorer survival time of GBM patients (141). Furthermore, it has been shown that melanoma cells from patient with melanoma specimens expressing high levels of ALDH1A1 and ALDH1A3 isoforms displayed a high self-renewal ability, and were more resistant to chemotherapeutic agents and more tumorigenic than ALDH− melanoma cells in non-obese diabetic (NOD)/severe combined immunodeficient (SCID) mice (139). It has also been noticed that the silencing of the ALDH1A gene by shRNA led to an arrest in cell cycle and apoptosis of ALDH1A+ melanoma cells, inhibition of tumor growth in vivo, and sensitized the ALDH1A+ melanoma cells to cytotoxic effects of chemotherapeutic drugs (139). These findings implicate that ALDH1A and ALDH3A isoforms are putative biomarkers for melanoma stem cells and constitute attractive therapeutic targets for treating melanoma patients. In the same way, human pancreatic ductal adenocarcinoma (PDAC) specimens have been observed to contain a side population exhibiting the gene expression signatures that are associated with pancreatic cancer stem cell–like characteristics and resistance to chemotherapeutic drugs (144). Among these genes, expression levels of ABCB1 multidrug transporter and CXC chemokine receptor 4 (CXCR4) were correlated with a worse survival of patients with pancreatic cancer (144).

Altogether, these studies have led to the identification and validation of gene expression signatures and potential diagnostic, prognostic, and predictive biomarkers related to stem cell–like cancer cells, EMT program, treatment resistance, and relapse of different aggressive cancers. Future investigations are however necessary to validate the expression of these gene signatures and their implications in the treatment resistance on larger cohorts of tumor tissue specimens from patients with cancer. In this regard, recent studies have also revealed the possibility to analyze the phenotypic features of exosomes secreted by cancer cells and CTCs, including circulating cancer stem/progenitor cells, to assess the tumor stage and risk of cancer progression, metastases, and disease relapse of patients with cancer.

**Molecular biomarkers of exosomes**

Accumulating lines of evidence have indicated that exosomes that are secreted by normal and cancer cells can act as key mediators in signal transduction mechanisms that are involved in short- and long-distance cell-to-cell communication (150–157). In fact, the exosomes are small microvesicles (sized about 50–100 nm) derived from cellular endocytosis that may contain specific lipids, proteins, mRNAs, and miRNAs encapsulated in a cholesterol-rich phospholipid membrane (150–157). More particularly, the exosomes that are released by cancer cells in their surrounding microenvironment and peripheral circulation may adhere via their antigenic surface molecules or transfer their cytoplasmic contents through membrane fusion to their targeted host cells, including other cancer cells, stromal cells, endothelial cells, and immune cells (Fig. 1; refs. 150–157). Hence, the shedding of exosomes by cancer cells under normoxic and hypoxic conditions may modulate immune system and promote the malignant behavior of recipient cells in their tumor microenvironment and angiogenesis as well as the formation of premetastatic niches, metastases at distant tissues and organs, and treatment resistance (Fig. 1 and Table 2; refs. 150–160). Importantly, recent advances in the development of isolation techniques of exosomes from some types of body fluids or circulating cancer stem/progenitor cells, to assess the tumor stage and risk of cancer progression, metastases, and disease relapse of patients with cancer.
Table 1. Characterization of molecular biomarkers detected in patient tissue specimens and their clinical significances in diverse aggressive and metastatic cancers

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Biomarker detection method</th>
<th>Number of patients/samples</th>
<th>Biomarkers and their diagnostic, prognostic, and predictive potentials</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 different cancer types including hematologic, brain, and epithelial cancers</td>
<td>Microarray and qRT-PCR analyses</td>
<td>1,153 clinical tumor specimens from patients with cancer diagnosed with acute myeloid leukemia, lymphoma, mesothelioma, medulloblastoma, glioma, and prostate, breast, lung, ovarian, or bladder epithelial cancers</td>
<td>An 11-gene signature that was associated with upregulation of stem cell–resembling expression profile of the BMI-1–regulated pathway has been shown to be a powerful predictor of prostate cancer progression and metastases. The expression of this 11-gene signature has also been associated with a short interval to disease recurrence, distant metastases and death after therapy of patients with 11 different cancer types.</td>
<td>(4)</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>Immunohistochemical staining</td>
<td>Tissue microarray (TMA) containing primary prostate tumor sections (n = 30) as well as 10 primary prostate tumors and their 10 matched bone metastases from patients with prostate cancer.</td>
<td>ALDH7A1 isoform was highly expressed in 83% clinical specimens of primary prostate tumors (TMA) as well as in 80% and 90% of prostate cancers and their matched bone metastases, respectively. These data suggest that ALDH7A1 could constitute a potential biomarker for the stratification of patients with prostate cancer at risk of developing metastatic disease.</td>
<td>(18)</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>Immunohistochemical staining of PSA− and PSA−/− cells in prostate cancer sections</td>
<td>Primary tumor specimens from untreated patients with Gleason score 7 (n = 10) and 9 or 10 (n = 10), and treatment-failed patients (n = 23)</td>
<td>High grade and recurrent prostatic adenocarcinoma specimens of patients were enriched in PSA−/− prostate cancer cells suggesting that PSA−/− prostate cancer cells with stem cell–like properties may play critical functions in the tumor regrowth after treatment initiation.</td>
<td>(17)</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>Immunohistochemical staining</td>
<td>76 primary tumor specimens from patients with prostate cancer with Gleason scores 6–10 plus 30 bone metastasis specimens from patients with prostate cancer.</td>
<td>The expression levels of EGFR, Ser473–pAkt, NF–κB p65, and MiC–1 proteins were significantly enhanced in the same subset of 76 cases of prostate cancer specimens during the disease progression and detected in a small subpopulation of CD133− prostate cancer cells and the bulk tumor mass of CD133− prostate cancer cells. All of these biomarkers were also overexpressed in 80% to 100% of 30 prostate cancer metastasis bone tissue specimens indicating their potential use as diagnostic and prognostic biomarkers.</td>
<td>(24)</td>
</tr>
</tbody>
</table>

(Continued on the following page)
Table 1. Characterization of molecular biomarkers detected in patient tissue specimens and their clinical significances in diverse aggressive and metastatic cancers (Cont’d)

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Biomarker detection method</th>
<th>Number of patients/samples</th>
<th>Biomarkers and their diagnostic, prognostic, and predictive potentials Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>Analysis of a gene expression signature from CD44⁺/CD24⁻/low cells and mammosphere (MS)-forming cancer cells in breast cancer specimens</td>
<td>The gene expression signature was analyzed in 36 tumors (18 luminal A/B, 13 basal-like, and 5 ErbB2-enriched). For therapeutic significance of signature, 18 patients with breast cancer pairs before and after therapy with letrozole or 12 patient pairs before and after docetaxel therapy were used.</td>
<td>A gene expression signature common to both CD44⁺/CD24⁻/low BCSCs and MS-forming breast cancer cells was mainly detected in patient’s primary tumors as the claudin-low molecular subtype expressing several EMT program-associated molecules. The CD44⁺/CD24⁻/low, MS and claudin-low signatures were also enriched in patient’s primary tumors after either endocrine letrozole-based therapy or docetaxel-based chemotherapy. These results support the potential application of the CD44⁺/CD24⁻/low-MS signature to predict the treatment resistance and relapse. (10)</td>
</tr>
<tr>
<td>Breast and prostate cancers</td>
<td>Comparative analyses of profiles of hormone-sensitive and -independent breast cancers and prostate cancer cell lines with gene expression data sets from patient’s breast cancers.</td>
<td>Breast ER-status signature was established from ER⁻ (hormone-independent) and ER⁺ (hormone-dependent) invasive breast cancer (n = 295) profile datasets and 18 different breast cancer cell lines (10 of them ER⁻). The gene signature data sets from 8 androgen-sensitive and androgen-independent prostate cancer cell lines was also used.</td>
<td>A common subset of 81 genes was differentially expressed between ER⁻ and ER⁺ breast tumor specimens and breast cancer cell lines as well as in androgen-independent versus androgen-sensitive prostate cancer cell lines. EGFR signaling elements were also enriched in ER⁻ breast and androgen-independent prostate cancer cell lines suggesting that the EGFR tumorigenic cascade may contribute to hormone-independent phenotypes of the breast cancer and prostate cancer cells. (11)</td>
</tr>
<tr>
<td>Breast and lung cancers</td>
<td>Comparative analyses of invasion assay and Affymetrix gene expression data on a panel of cancer cell lines with chemosensitivity data.</td>
<td>Invasion-associated genes established from 60 human cancer cell lines developed by the National Cancer Institute were compared with chemosensitivity data of 99 anticancer drugs and clinical data from adjuvant chemotherapy cohorts in 508 breast and 71 patients with lung cancer and a cohort of untreated patients (controls).</td>
<td>An 8-gene signature (EGFR, integrin-α₃, myosin light chain kinase, retinoic acid induced protein 14, AHNAK nucleoprotein, glutaminase, interleukin-32, and nicotinamide N-methyltransferase) was associated with the invasion and sensitivity of a panel of 60 tumor cell lines to paclitaxel, docetaxel, erlotinib, everolimus, and dasatinib. The 8-gene signature also predicted the relapse-free survival for patients with breast and lung cancer. (14)</td>
</tr>
</tbody>
</table>

(Continued on the following page)
Table 1. Characterization of molecular biomarkers detected in patient tissue specimens and their clinical significances in diverse aggressive and metastatic cancers (Cont’d)

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Biomarker detection method</th>
<th>Number of patients/samples</th>
<th>Biomarkers and their diagnostic, prognostic, and predictive potentials</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non–small cell lung cancer (NSCLC)</td>
<td>Immunohistochemical analysis</td>
<td>Various histological tissue specimens of lung squamous cell carcinoma (SCC) and lung adenocarcinomas in 2 independent large TMA sets ($n_1 = 287$ and $n_2 = 511$) were used.</td>
<td>A marked nuclear expression of SOX2 embryonic stem cell transcriptional factor was detected in all normal bronchial epithelia, alveolar bronchiolization structures, and premalignant lesions in SCC development (hyperplasia, dysplasia, and carcinoma in situ). In contrast, SOX2 protein expression was not seen in all normal alveoli and atypical adenomatous hyperplasias. Moreover, SOX2 expression was greatly higher in lung SCCs compared with lung adenocarcinomas. (143)</td>
<td></td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>Whole-genome expression analyses of side population cells and main non-side (non-side population) cell fraction isolated from human pancreatic cancer resections specimens by FACS</td>
<td>Side population cells were obtained from human PDAC specimens ($n = 32$) and the prognostic value of the side population gene signature was validated in a large independent series of PDAC patients ($n = 78$).</td>
<td>32 PDAC specimens contained a side population cell subpopulation exhibiting an upregulation of genes associated with markers of putative pancreatic cancer stem and therapy resistance. The validation of side population cell-derived gene signatures of 32 or 10 up- or downregulated genes in a different set of 78 PDAC samples has also indicated that the expression levels of ABCB1 multidrug transporter and CXCR4 were correlated with worse patient survival suggesting their potential used as prognostic biomarkers and therapeutic targets. (144)</td>
<td></td>
</tr>
<tr>
<td>Brain cancer</td>
<td>The mRNA expression levels of PTEN, SHH, PTCH1, and GLI1 were determined by real-time PCR assays.</td>
<td>55 GBM tissue specimens of patients (age range = 29–75) who were diagnosed with de novo glioblastoma and treated with external beam radiation therapy to 60 Gy and chemo-therapy were used. The GBM samples were separated into a PTEN-expressing group and a PTEN-deficient group on the basis of their PTEN expression.</td>
<td>The expression levels of SHH and GLI1 were significantly higher in PTEN-expressing GBM specimens than in PTEN-deficient GBMs. The higher expression levels of SHH, PTCH1, and GLI1 in PTEN-coexpressing GBM specimens were also associated with reduced survival of patients. These data indicate that hedgehog signaling elements may constitute potential prognostic biomarkers and molecular targets for individualized treatment of GBM patients overexpressing SHH/GLI1. (141)</td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>Analyses of ALDH activity by Aldefluor assay and gene expression by microarray analyses, qRT-PCR and immunohischemistry</td>
<td>3 primary and 6 metastatic tumors from melanoma patients</td>
<td>8 patient’s tumors harbored small ALDH$^+$ subpopulations, ranging from 0.08% to 1.15%. The gene expression signatures of melanoma cells expressing high levels of ALDH1A and ALDH3A from patient’s melanoma specimens were characterized by expression of some genes associated with stem cell functions. (139)</td>
<td></td>
</tr>
</tbody>
</table>
Table 2. Potential applications of molecular biomarkers of circulating exosomes for the diagnosis, prognosis, and prediction of treatment responses of diverse aggressive and metastatic cancers

<table>
<thead>
<tr>
<th>Potential application of exosomes</th>
<th>Cancer type</th>
<th>Exosome source and purification and detection methods</th>
<th>Results and their significances</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic biomarkers</td>
<td>Ovarian cancer</td>
<td>Tumor-derived exosomes were isolated from peripheral blood of 50 women diagnosed with serous papillary adenocarcinoma of the ovary (stages I–IV) using a MACS procedure with anti-EpCAM coupled to magnetic microbeads.</td>
<td>An 8 diagnostic miRNA signature (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205, and miR-214) was detected in ovarian tumor-derived EpCAM-exosomes and ovarian tumor specimens isolated from same patients with cancer. In contrast, these exosomal miRNAs were not be detected in normal controls. Moreover, the levels of circulating exosomes detected in women increased with the stages I–IV of ovarian cancer.</td>
<td>(166)</td>
</tr>
<tr>
<td>Diagnostic biomarkers</td>
<td>Prostate cancer</td>
<td>Exosomes were prepared by differential centrifugation from urine samples of 11 patients with prostate cancer.</td>
<td>The expression of prostate cancer biomarkers, including prostate cancer gene-3 (PCA-3) and TMPRSS2:ERG gene fusion, was detected in urinary exosomes suggesting their potential use for the diagnosis and monitoring of patients with prostate cancer.</td>
<td>(161)</td>
</tr>
<tr>
<td>Diagnostic biomarker</td>
<td>Brain tumor</td>
<td>Exosomes were purified by differential centrifugation from serum samples from 25 GBM patients and 30 healthy individuals.</td>
<td>Tumor-specific and constitutively active EGFRvIII mutant was detected by RT-PCR in serum exosomes from 7 of 25 (28%) GBM patients whereas EGFRvIII mRNA was not detected in serum exosomes from 30 normal individuals used as controls.</td>
<td>(152)</td>
</tr>
<tr>
<td>Diagnostic and prognostic biomarker</td>
<td>Esophageal squamous cell cancer (ESCC)</td>
<td>Exosomes were extracted from the serum samples of patients with ESCC and benign diseases without systemic inflammation.</td>
<td>The exosomal miR-21 expression was significantly upregulated in serum samples from patients with ESCC versus benign diseases without systemic inflammation. Exosomal miR-21 positively correlated with tumor progression and aggressiveness, lymph node status, and the presence of metastasis with inflammation and clinical stage without inflammation.</td>
<td>(165)</td>
</tr>
<tr>
<td>Diagnostic and prognostic biomarkers</td>
<td>Melanoma</td>
<td>Exosomes were purified by centrifugation from peripheral blood samples from stage I–IV melanoma subjects.</td>
<td>An exosome-specific melanoma signature comprised of MET, tyrosinase-related protein-2, very late antigen-4, HSP70, and HSP90 has been associated with stage and outcome of patients with melanoma.</td>
<td>(169)</td>
</tr>
<tr>
<td>Predictive biomarker</td>
<td>Breast cancer</td>
<td>Exosomes were isolated from HER2-overexpressing breast carcinoma cell lines SKBR3 and BT474 or breast cancer patient’s serum samples.</td>
<td>Exosomes from HER2+ SKBR3 and BT474 tumor cell-conditioned supernatants or breast cancer patients’ serum expressing HER-2 have been observed to interact with humanized antibody trastuzumab. Moreover, the data from functional assays have also revealed that exosomes suppressed the inhibitory activity of trastuzumab on the SKBR3 cell proliferation whereas lapatinib had no effects. These findings suggest that HER2+ exosomes can modulate the sensitivity of breast cancer cells to trastuzumab, and consequently HER2-driven tumor aggressiveness.</td>
<td>(172)</td>
</tr>
</tbody>
</table>
with migration, invasion, immune modulation, angiogenesis, and metastasis were also detected in exosomes (162). These oncogenic products comprise EGFR, epithelial cell surface antigen (EpCAM), proliferation cell nuclear antigen (PCNA), tubulin β-3 chain (TUBB3), apolipoprotein E (APOE), and claudin 3 (CLDN3; ref. 162). Moreover, the exosomes expressing T-cell receptor (TCR), CD20, HLA-DR, B7-2, HER2, CA125, and histone H2A have been detected in 85.4% (35/41) of ascites samples from patients with ovarian cancer (167). It has also been shown that the exosomes induced the apoptosis of precursor and mature dendritic cells and peripheral blood mononuclear cells (PBMC) and impaired the cytotoxic activity of PBMCs in the presence of dendritic cells suggesting their implication in the modulation of antitumor immunity (167).

In addition, the tumor-specific and constitutively active form of EGFR designated as EGFRVIII mutant has also been detected in serum exosomes from 7 of 25 patients with glioblastoma (152). It has been noted that EGFRVIII protein expressed by glioma cells may be transferred via exosomes to other glioma cells lacking EGFRVIII, and thereby promoted their oncogenic transformation via the activation of PI3K/Akt and mitogen-activated protein kinase (MAPK) pathways (Figs. 1 and 2A and Table 2; ref. 153). These molecular events induced the changes in the expression of EGFRVIII-regulated genes such as vascular growth factor (VEGF), Bcl-xL, and p27 in host glioma cells and increased

<p>| Table 2. Potential applications of molecular biomarkers of circulating exosomes for the diagnosis, prognosis, and prediction of treatment responses of diverse aggressive and metastatic cancers (Cont’d) |
|-------------------------------------------------|-----|-------------------------------------------------|-------------------------------------------------|</p>
<table>
<thead>
<tr>
<th>Potential application of exosomes</th>
<th>Cancer type</th>
<th>Exosome source and purification and detection methods</th>
<th>Results and their significances</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic and predictive biomarker</td>
<td>Prostate cancer</td>
<td>Exosomes were purified by ultracentrifugation from plasma and serum samples from 39 patients with prostate cancer, 20 benign prostatic hyperplasia (BPH) patients, 8 recurrent prostate cancers and 16 healthy controls.</td>
<td>Survivin level was significantly upregulated in the tumor-derived exosomes compared with those from BPH and controls. Exosomal survivin level was also higher in patients that had relapsed after chemotherapeutic treatment compared with controls.</td>
<td>(171)</td>
</tr>
<tr>
<td>Diagnostic, prognostic and predictive biomarkers</td>
<td>Brain cancer</td>
<td>Profiling of circulating exosomes labeled with target-specific magnetic nanoparticles was directly performed in blood samples of 24 GBM patients and 8 healthy volunteers using microfluidic chip. Exosomes were detected with miniaturized nuclear magnetic resonance system</td>
<td>Data of protein profiling of circulating exosomes have indicated that the expression of a combination of 4 markers (EGFR, EGFRVIII mutant, podoplanin, and cytosolic isocitrate dehydrogenase 1) considerably improved the detection accuracy (&gt;90%) as compared with a single marker (&lt;76). Circulating exosome profiling also predicted treatment outcomes of GBM patients and differentiated between responders and nonresponders to a treatment with alkylating agent, temozolomide plus radiation.</td>
<td>(170)</td>
</tr>
</tbody>
</table>
their anchorage-independent growth capacity (153). It has also been observed that exosomes released from glioblastoma tumor cells also contained mRNA, miRNA, and angiogenic proteins that could be transferred to host cells, including normal brain microvascular endothelial cells. Hence, the activated EGFR or EGFRVIII may stimulate MAPK and Akt pathways and expression of their targeted genes, including VEGF, in host cancer cells and endothelial cells in their surrounding tumor microenvironment. VEGF released by endothelial cells in turn can activate in an autocrine manner the VEGFR2 cascade and tumor angiogenesis. Of therapeutic interest, the inhibition of exosome secretion from cancer cells carried by shRNA silencing of Rab27a/b, using an inhibitor of sphingomyelinase (GW4869) or annexin/diannexin and which represent potential strategies to prevent the promoting effects of exosomes on tumor progression, angiogenesis, and metastasis is indicated. B, the elimination of tumor cell–derived exosomes from the entire circulatory system, which can be performed by extracorporeal hemofiltration using novel medical devices such as an affinity plasmapheresis platform designated as Aethlon ADAPT system is illustrated. C, the systemic delivery of therapeutic agents incorporated in cellular or synthetic exosomes and which are able to inhibit the functions of tumor-specific mRNAs, miRNAs such as spherical nucleic acid constructs, and/or oncogenic products in target cancer cells is also illustrated.
Importantly, several lines of experimental evidence have also indicated that the exosomes may be involved in the formation of premetastatic niches and transfer of more aggressive and drug-resistance phenotypes to cancer cells and modulation of treatment responses of patients with cancer (Table 2; refs. 150, 169–175). For instance, CD133-expressing exosomes purified from FEMX-1 cell line, which was derived from a lymph node metastasis of a patient with malignant melanoma, have been observed to express several prometastatic proteins, including CD44, MAPK4K, GTP-binding proteins, ADAM10, and annexin A2 and high levels of miRNAs with cancer-related functions (173). It has been shown that primary melanoma-derived exosomes can induce the recruitment and growth of melanoma cells to sentinel lymph nodes in vivo by inducing extracellular matrix deposition and vascular proliferation in the lymph nodes (174). Moreover, the exosomes from highly metastatic melanomas also contributed to the premetastatic niche formation through the upregulation of the MET oncoprotein in CD45+/KIT+ Tyr/tyrosine kinase with immunoglobulin-like and EGF-like domains-2 (TIE2) bone marrow-derived progenitor cells (Fig. 1; ref. 169). The enhanced expression of MET by bone marrow progenitor cells resulted in their reprogramming toward proangiogenic and prometastatic phenotypes (169). The gene signature of exosomes released by melanoma, including MET, tyrosinase-related protein-2, very late antigen-4, HSP70, and HSP90, has also been associated with a poor prognosis of patients with melanoma (Table 2; ref. 169). Moreover, it has been reported that the exosomes isolated from serum samples of patients with prostate cancer promoted the proliferation and invasion of prostate cancer cell lines whereas the exosomes from age-matched healthy controls have not significant effects (150). The exposure of DU145 and 22Rv1 prostate cancer cells to exosomes from serum samples of patients with prostate cancer treated with docetaxel was also effective at enhancing their docetaxel resistance as compared with exosomes from untreated prostate cancer patient’s sera (150). It has also been noticed that docetaxel-resistant DU145RD and 22Rv1RD cell lines secreted the exosomes expressing P-glycoprotein, which could be transferred and conferred docetaxel resistance to parental DU145 and 22Rv1 cell lines (Fig. 1; ref. 150). The PCR-based analyses of urine samples from patients with prostate cancer have also indicated that the transcripts of prostate cancer gene-3 (PCA-3) and TMPRSS2;ERG gene fusion were detected in urinary exosomes suggesting their potential use as a noninvasive method for the diagnosis and follow-up of patients with prostate cancer (161). Moreover, it has also been shown that the exosomes released by SKBR3 breast cancer cells overexpressing HER2 oncoprotein interfered with the antioxidant activity of the anti-HER2 antibody, trastuzumab (Herceptin; ref. 172).

**Therapeutic applications of exosomes**

The molecular targeting of tumor cell–derived exosomes by interfering with their biosynthesis, secretion, and/or interactions with cell antigens or receptors also represents a promising approach to prevent the cancer progression, premetastatic niche formation, and metastases at distant sites (Fig. 2; refs. 160, 169, 176–179). For example, the targeting of neutral sphingomyelinase 2, which is involved in the ceramide biosynthesis and upregulation of exosome secretion, with chemical drug GW4869 has been shown to inhibit the lung metastases in lung cancer cell-bearing mice in vivo (176). Moreover, the interference with molecular pathways of exosome secretion by shRNA silencing of small GTPase Rab27a or Rab27b or 2 Rab27 effectors, known as Slp4 and Slac2b, also inhibited the exosome secretion by cervical adenocarcinoma HeLa cells, 4T1 and TS/A mammary carcinoma cells, and melanoma cells (169, 177, 178). It has also been noted that Rab27a blockade resulted in decreased primary tumor growth and lung dissemination of a metastatic carcinoma (4T1), but not of a nonmetastatic carcinoma (TS/A; ref. 177). In A431 human tumor xenografts in mice, angiogenic endothelial cells stained positively for human EGFR and phospho-EGFR, whereas treatment with annexin homodimer, dia-"nnexin which cloaks phosphatidylserine residues on the surfaces of exosomes led to a reduction of tumor growth rate and microvascular density (Fig. 2A; ref. 160). Of particular clinical interest, a novel medical device using an affinity plasmapheresis platform termed as Aethlon ADAPT system was also effective to perform extracorporeal hemofiltration and elimination of tumor cell–derived exosomes from the entire circulatory system (Fig. 2B; ref. 179).

Recent investigations have also revealed that exosomes could be used as natural cell–derived membrane vehicles for systemic delivery of therapeutic agents interfering with the functions of tumor-specific mRNAs, miRNAs, and oncogenic products in target cells as well as immune regulatory tools in cancer immunotherapy (Fig. 2C; refs. 180–183). As a matter of fact, exosomes engineered to deliver spherical nucleic acid constructs into PC3 prostate cancer cells downregulated miR-21 target by approximately 50% (182). Furthermore, it has been shown exosomes that are released by tumor cells and dendritic cells may be used to elicit-specific immune responses against established tumors (180, 181). For instance, the data from a phase I clinical trial have indicated that a combination of autologous ascites-derived exosomes with granulocyte macrophage colony-stimulating factor (GM-CSF) was safe and well tolerated and induced tumor antigen-specific cytotoxic T-cell responses without side effects in patients with advanced colorectal cancer (180). Together these data suggest important roles of exosomes secreted by cancer cells in their surrounding microenvironment in the acquisition of a more malignant behavior by host cancer cells and promoting immune escape and tumor neovascularization during cancer progression. Moreover, the exosomes can play critical functions in the establishment of premetastatic niches, recruitment, and homing of cancer cells at distant tissues and organs, metastases, and treatment resistance. Hence, these results support the interest to use the exosome-
specific biomarkers as new diagnostic, prognostic, and predictive indicators and to develop new exosome-based-targeted therapies for treating aggressive and metastatic cancers.

**Molecular biomarkers of CTCs**

The enumeration of CTCs isolated from whole blood samples of patients with metastatic cancers before or posttreatment initiation and characterization of their molecular biomarkers may constitute a noninvasive and real-time method for improving accuracy of diagnosis and prognosis and choice of their therapeutic management, including use of appropriate targeted therapy (16, 31–35, 184). Several strategies, including CellSearch platform, microfluidic devices, and cell size–based separation methods, have been developed to detect, enrich, and isolate rare CTCs from peripheral blood samples using different specific antibodies or size-based filters (Fig. 1 and Table 3; refs. 16, 31–34). These detection techniques involve the CTC immunocapture from peripheral blood samples using different specific antibodies or size-based filters (Fig. 1 and Table 3; refs. 16, 31–34). More particularly, the CellSearch technology, which consists to use immunomagnetic beads coated with an antibody directed against EpCAM molecules, can allow researchers to isolate epithelial cancer cells expressing EpCAM surface marker (16, 31, 33–35, 184, 185). In a second step, the analyses of different biomarkers of the interest expressed by captured CTCs can be performed by quantitative real-time reverse transcription PCR (qRT-PCR) using DNA extracted from CTCs or immunofluorescence staining of CTCs (Fig. 1; refs. 16, 31, 34, 184). The biomarkers of CTCs include stem cell–like markers (CD133, CD44, ALDH, and ABC multidrug transporters), cytokeratins, EGFR, EGFRvIII, HER2, and K-Ras as well as the absence of the leukocyte-specific marker CD45 (Table 3; refs. 16, 31, 34, 184). Hence, it has been observed that the number and phenotypic features of CTCs captured using CellSearch assay, microfluidic CTC-chips, and other detection techniques give significant information on the treatment benefit and helped to predict the overall outcome of patients with locally advanced and metastatic breast, prostate, ovarian, pancreatic, lung, colorectal, and pancreatic cancers (Table 3; refs. 16, 31–35, 37, 184, 186–189). For instance, the characterization of CTCs from patients with metastatic CRPC has indicated that the majority of CTCs coexpressed epithelial proteins (EpCAM, cytokeratins, and E-cadherin), mesenchymal markers (vimentin, N-cadherin, and O-cadherin), and the stem cell–like marker CD133 (34).

In addition, the results of qRT-PCR analyses of CTCs from patients with breast cancer have also indicated a direct relationship between the expression of stem cell–like markers such as Nanog, Oct3/4, Sox-2, nestin, and CD34 on CTCs and the stage of the disease progression (36). Moreover, the analyses of blood samples from 502 patients with breast cancer with the AdnaTest BreastCancer Select for the detection of EpCAM, MUC1, HER2, and β-actin transcripts have revealed that CTCs were detected in 19% of samples, and 29% samples expressed at least one of EMT markers (twist1, Akt2, and PI3Kα) whereas ALDH1 stem cell–like marker was detected in 14% of the samples (38). In another study, CTCs were also detected in 31% of 226 blood samples from 39 patients with metastatic breast cancer and 62% were positive for at least one of EMT markers and 69% for ALDH1 (39). It has also been noticed that the expression of EMT markers and ALDH1 was detected in 62% and 44% of patients with breast cancer that were nonresponders to the therapy whereas only 10% and 5% of the responders expressed these markers, respectively suggesting their potential use as predictive biomarkers (39).

More recently, single CTCs and multicellular clusters in a viable state have also been isolated from bloodstream of patients with metastatic lung cancers by dead flow fractionation (40). This size-based separation method may overcome the problems associated with the immunocapture with antibodies that is dependent of antigens expressed by CTCs (40). The number of CTCs detected by dead flow fractionation in whole blood samples from 20 patients with metastatic lung cancer was 39.1 ± 24.8 CTCs/mL whereas CTCs in blood samples from 20 healthy individuals was negligible (0.79 ± 0.42 CTCs/mL; ref. 40). It has also been observed that the CTC population detected in blood samples from patients with advanced lung cancer contained cells coexpressing cytokeratin and CD133 stem cell–like marker (40). Moreover, the qRT-PCR analyses of peripheral blood samples from patients with primary melanoma (early stages I–II, n = 154) and metastatic melanoma (late stages III–IV, n = 76) have indicated that all samples contained CTCs (41). It has also been noted that melan-A known as melanoma antigen and stem cell–like marker, ABCB5 multidrug transporter were expressed in 45% and 49% of patients showing melanoma recurrence after treatment initiation, respectively (41).

The use of specific biomarkers of CTCs, including stem cell–like markers, represents a promising strategy for improving the diagnosis, prognosis, and therapeutic management of patients with aggressive and metastatic cancers.

**Conclusions and Perspectives**

The characterization of gene products expressed in tumor tissue specimens and CTCs from patients with cancer and exosomes released by cancer cells has led to the identification and validation of some gene signatures and potential stem cell–like markers. These altered gene products could be used as noninvasive diagnostic, prognostic, and predictive tools in conjunction for monitoring the risk of tumor progression and metastases and determining the choice of therapeutic treatments of patients with cancer. Furthermore, the molecular targeting of specific markers of cancer stem/progenitor cells, CTCs, and exosomes also represents a potential strategy could prevent cancer progression and metastases and overcome the treatment resistance and disease relapse of patients with cancer.
Table 3. Characterization of molecular biomarkers of CTCs and their clinical significances in diverse aggressive and metastatic cancers

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>CTC detection method</th>
<th>Number of CTCs detected by patients/samples</th>
<th>Biomarkers and their diagnostic, prognostic, and predictive potentials</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>AdnaTest Breast Cancer Select for detection of EpCAM, MUC1, HER2 and β-actin transcripts</td>
<td>CTCs were detected by AdnaTest in 19% of 502 blood samples from patients with breast cancer. Blood samples from 502 primary patients with breast cancer versus 30 healthy donor samples were positive for CTCs characterized by RT-PCR by the expression of at least one EMT marker (twist, Akt2, and PI3Kα) whereas 97% of 30 healthy donor samples investigated were negative. Moreover, 14% samples positive for CTCs expressed ALDH1 stem cell-like marker whereas 95% of 30 healthy donor samples were negative.</td>
<td>(38)</td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>AdnaTest Breast Cancer Select for detection of EpCAM, MUC1, and HER2 transcripts</td>
<td>226 blood samples from 39 patients with metastatic breast cancer obtained during their follow-up of chemotherapy, hormonal, or trastuzumab antibody-based treatment</td>
<td>CTCs were detected by AdnaTest in 31% of 226 blood samples. The samples positive for CTCs were characterized by RT-PCR by the expression of at least one EMT marker (twist, Akt2, and PI3Kα) and ALDH1 in 62% and 69% cases as compared with 7% and 14% in blood samples negative for CTCs, respectively. The EMT and ALDH1 expression levels in blood samples from patients unresponsive to therapy were of 62% and 44% relative to only 10% and 5% in responders.</td>
<td>(39)</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>CellSearch EpCAM-based immunocapture method</td>
<td>Data from analyses performing by CellSearch system and immunostaining have revealed that over 75% of CTCs detected in blood samples from patients with metastatic breast cancer coexpressed epithelial markers (EpCAM and E-cadherin) and mesenchymal proteins (vimentin and N-cadherin).</td>
<td>(34)</td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Microfluidic capture of CTCs with epithelial- and tumor-specific antibodies directed against EpCAM, EGFR, and HER2</td>
<td>Blood samples from 41 patients with metastatic breast cancer at various stages of treatment.</td>
<td>CTCs were detected in 41% of blood samples from patients with breast cancer. CTCs expressed epithelial (cytokeratins, EpCAM, and cadherin 1) and/or mesenchymal markers (fibronectin, cadherin 2, and serpin peptidase inhibitor, clade E). The enrichment of mesenchymal CTCs was associated with disease progression and expression of TGF-β signaling pathway components.</td>
<td>(37)</td>
</tr>
</tbody>
</table>

(Continued on the following page)
**Table 3. Characterization of molecular biomarkers of CTCs and their clinical significances in diverse aggressive and metastatic cancers (Cont’d)**

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>CTC detection method</th>
<th>Number of CTCs detected by patients/samples</th>
<th>Biomarkers and their diagnostic, prognostic, and predictive potentials</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovarian cancer</td>
<td>The monocyte blood fraction containing CTCs was enriched by 2-layer density gradient and RNA extracted from the enriched cell fraction</td>
<td>Blood samples from 216 patients with epithelial ovarian cancer obtained before primary treatment and 6 months after adjuvant platinum-based chemotherapy and 39 cases of healthy women</td>
<td>CTCs were detected in 24.5% of the baseline and 20.4% of the follow-up samples. The detection of CTCs correlated with the presence of ascites, suboptimal debulking and elevated CA-125, and human epididymis protein 4 (HE-4) levels. Moreover, the CTC detection was more frequent in platinum resistant patients than in the group sensitive to platinum treatment and indicative of poor outcome of patients.</td>
<td>(187)</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>CellSearch system</td>
<td>Blood samples from 26 patients with pancreatic cancer</td>
<td>CTCs expressing cytokeratins were detected in 42% of blood samples and patients with pancreatic cancer with CTCs exhibited significantly shorter overall survival.</td>
<td>(188)</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>CellSearch system or isolation by size of epithelial tumor cells (ISET)</td>
<td>Blood samples from 54 patients with pancreatic cancer</td>
<td>CTCs were detected by CellSearch EpCam-based immunocapture method and ISET in 40% versus 93% of patients with pancreatic cancer, respectively. The immunostaining analyses have also indicated that CTCs expressed variable levels of EpCam, pan-cytokeratin, E-cadherin, vimentin, and cytokeratin 7.</td>
<td>(186)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>Pre- and postoperative EpCAM based-flow cytometry analyses</td>
<td>Blood samples from 76 patients with colorectal cancer undergoing surgical resection</td>
<td>CTCs were detected in 71% patients preoperatively, and all metastatic patients showed high levels of CTCs. Colorectal tumor surgical resection was associated with a significant decrease in CTCs. A high postoperative level of CTCs was also related to cancer relapse. The progression-free survival rate of patients with colorectal cancer without CTCs was increased from 16% to 86%, with a reduction in the risk of disease relapse greater than 90%.</td>
<td>(185)</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>Centrifugal force-based separation technique termed dean flow fractionation (DFF)</td>
<td>Blood samples from 20 patients with metastatic lung cancer at different stages of treatment versus 20 blood samples from healthy individuals</td>
<td>5 to 88 CTCs were detected by DFF in all blood samples analyzed from patients with metastatic lung cancer whereas healthy subjects had a negligible number of CTCs. Moreover, the data from immunostaining have revealed that CTCs detected in blood samples from patients with advanced lung cancer coexpressed cytokeratin and CD133 stem cell-like marker.</td>
<td>(40)</td>
</tr>
</tbody>
</table>

*(Continued on the following page)*
Future investigations are however required to optimize the sensitivity and reproducibility of immunocapture methods used for the enrichment and enumeration of CTCs and circulating exosomes from whole blood samples to consider their low number, potential heterogeneity, and specific biomarkers. Indeed, the detection and purification of rare CTCs, including circulating cancer stem cells, and circulating exosomes may be obscured by the nonspecific background of other hematopoietic cell types and overwhelming material in whole blood samples. Therefore, the optimization of in vivo detection platforms suitable for a continuous monitoring of whole blood volume could markedly improve the probability to detect rare CTCs, including circulating cancer cells with stem cell–like features. Moreover, the use of additional antibodies directed against epithelial, mesenchymal, and/or stem cell–like surface markers of CTCs could be included in immunoaffinity capture methods, such as CellSearch.

Table 3. Characterization of molecular biomarkers of CTCs and their clinical significances in diverse aggressive and metastatic cancers (Cont’d)

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>CTC detection method</th>
<th>Number of CTCs detected by patients/samples</th>
<th>Biomarkers and their diagnostic, prognostic, and predictive potentials Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non–small cell lung cancer (NSCLC)</td>
<td>CellSearch system or mutation detection in circulating tumor DNA</td>
<td>Blood samples from 41 patients with relapsed or refractory NSCLC enrolled in a single-arm phase II multicenter trial with erlotinib and pertuzumab</td>
<td>CTCs were detected using CellSearch system in 78% of patients with NSCLC and a greater baseline of CTC counts was associated with a response to treatment by response evaluation criteria in solid tumor (RECIST). A decrease of CTC counts upon treatment of patients was also related with FDG-PET and RECIST response and longer progression-free survival. Data from RT-PCR analyses have also indicated that the detection of mutation in EGFR in ctDNA and DNA isolated from CTCs was associated with a most substantial decrease in CTC counts over the course of treatment of NSCLC patients with erlotinib and pertuzumab. (184)</td>
</tr>
<tr>
<td>Epithelial malignancies</td>
<td>Multimarker quad-μ-NMR nuclear magnetic resonance (μ-NMR)</td>
<td>Biopsies of 58 patients with epithelial malignancies including breast (n = 4), gastrointestinal (n = 17), genitourinary (n = 4), gynecologic (n = 7), pancreatic (n = 10), lung (n = 9), and poorly differentiated adenocarcinoma (n = 7) and 6 patients with benign diagnosis</td>
<td>Data from quad μ-NMR expression profiles of the biopsies obtained by the fine needle aspiration of 58 patients with different epithelial malignancies have revealed that the combined analyses of EpCAM, HER2, EGFR, and MUC1 markers may be used to achieve the diagnosis of patients with cancer in 99.2% of samples. (189)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>RNA isolation from whole blood samples</td>
<td>Blood sample from 230 melanoma patients, including 154 patients at early stages I–II and 76 patients at late stages III–IV versus 152 cases of healthy individuals</td>
<td>Data from quantitative RT-PCR analyses have indicated that 92% of melanoma patients expressed MLANA, TGF-β2, PAX3d, MCAM, and ABCG5 multidrug transporter. Importantly, the expression of MLANA and ABCG5 could predict disease recurrence whereas MLANA expression was associated with a poor outcome of patients with melanoma after treatment. (41)</td>
</tr>
</tbody>
</table>
platform and microfluidic ships, to detect the EpCAM™-CTCs or exosomes. It will also be of interest to further establish the relationship between the expression levels of EMT process- and stem cell–like markers detected on captured CTCs and exosomes and the stage of tumor progression, treatment response, and survival rate using a large cohort of patients with cancer. Hence, the combined use of these new biomarkers detected in primary and metastatic tumor tissues, CTCs, and exosomes should lead to the development of multiplex biomarker approaches for improving the accuracy of current diagnostic and prognostic tests and efficacy of individualized treatments for patients with cancer. Of clinical relevance, the development of new nanotheranostic platforms for the combined in vivo detection by imaging and nanobubble-based targeted therapies of CTCs and circulating exosomes also may constitute a promising approach for real-time diagnosis and treatment of patients with aggressive and metastatic cancers.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Grant Support
The authors were supported by the grants from the NIH (R01CA138791, EDRN U01, and SPORE: P50 CA127297).

Received August 1, 2013; revised November 2, 2013; accepted November 6, 2013; published OnlineFirst November 22, 2013.

References
tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS ONE 2012;7:e46391.


Cancer Epidemiology, Biomarkers & Prevention


Molecular Biomarkers of Cancer Stem/Progenitor Cells Associated with Progression, Metastases, and Treatment Resistance of Aggressive Cancers

Murielle Mimeault and Surinder K. Batra